🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo (QVA149)

Found 20 matching trials

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

PHASE3

This study will assess the efficacy, safety and tolerability of indacaterol...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-12

Trial ID

NCT01712516

Treatments Being Tested

QVA149 QAB149 NVA237 Placebo

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The purpose of this study was to determine whether a fixed dose combination...

Status

Completed

Location

Novartis Investigative Site

Start Date

2014-11-30

Trial ID

NCT02233543

Treatments Being Tested

QVA149 QVA149 Placebo

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to compare the efficacy and safety/tolerabilit...

Status

Completed

Location

Novartis Investigative Site

Start Date

2011-03

Trial ID

NCT01315249

Treatments Being Tested

indacaterol and glycopyrronium (QVA149)Placebo to fluticasone/salmeterol fluticasone/salmeterol Placebo to indacaterol and glycopyrronium (QVA149)

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

PHASE3

The study will assess the long-term safety of the fixed combination product...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01610037

Treatments Being Tested

QVA149 Tiotropium placebo

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

PHASE3

The purpose of this study is to demonstrate that the efficacy of the combin...

Status

Completed

Location

Novartis Investigative Site

Start Date

2015-07-27

Trial ID

NCT02487498

Treatments Being Tested

QVA149 Umeclidinium/vilanterol Placebo (umeclidinium/vilanterol )Placebo (QVA149)

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

PHASE3

This study is to assess the safety and tolerability of two different doses ...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01682863

Treatments Being Tested

QVA149 QVA149 QAB149 Placebo

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The study assessed the safety and efficacy of the fixed combination product...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-05

Trial ID

NCT01529632

Treatments Being Tested

QVA149 NVA237 QAB149 Placebo

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

PHASE3

This study is designed to assess the effect of QVA149 (110/50 ug q.d.) vers...

Status

Completed

Location

Novartis Investigative Site

Start Date

2014-04

Trial ID

NCT01996319

Treatments Being Tested

QVA149 Placebo

Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study assessed the effect of once-daily indacaterol and glycopyrronium...

Status

Completed

Location

Novartis Investigative Site

Start Date

2011-02

Trial ID

NCT01294787

Treatments Being Tested

indacaterol and glycopyrronium bromide (QVA149)placebo tiotropium

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

An investigational inhalation product (QVA149) for the treatment of patient...

Status

Completed

Location

Novartis Investigator Site

Start Date

2007-11

Trial ID

NCT00558285

Treatments Being Tested

indacaterol/glycopyrrolate indacaterol glycopyrrolate placebo

Previous Next